Abstracts tagged "psoriasis"

Abstract Number: 882 • 2017 ACR/ARHP Annual Meeting
A New Model of Care for Improving Early Rheumatology Access of Psoriatic Arthritis Patients
Keith Colaco^1,2, Dana Jerome³, Jensen Yeung^4,5, Noah Ivers^6,7,8, Carol Kitai⁷, Chandra Farrer³ and Lihi Eder^1,9, ¹Women's College Research Institute, Women's College Hospital, Toronto, ON, Canada, ²Institute of Medical Science, University of Toronto, Toronto, ON, Canada, ³Rheumatology, Women's College Hospital, Toronto, ON, Canada, ⁴Dermatology, Women's College Hospital, Toronto, ON, Canada, ⁵University of Toronto, Toronto, ON, Canada, ⁶Institute for Clinical Evaluative Sciences, Toronto, ON, Canada, ⁷Women's College Hospital, Toronto, ON, Canada, ⁸Family and Community Medicine, University of Toronto, Toronto, ON, Canada, ⁹Medicine, University of Toronto, Toronto, ON, Canada
Background/Purpose: The prevalence of undiagnosed psoriatic arthritis (PsA) in psoriasis patients is high, with delays in diagnosis contributing to poor patient outcomes. We aimed to…
Abstract Number: 989 • 2017 ACR/ARHP Annual Meeting
Impact of DMARD Treatment on Risk of Repeat Cardiovascular Events Among Patients with Rheumatoid Arthritis, Psoriatic Arthritis, or Psoriasis
Jeffrey A. Sparks¹, Tamara Lesperance², Neil A. Accortt³ and Daniel H. Solomon⁴, ¹Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ²DOCS Global, Inc., North Wales, PA, ³Center for Observational Research, Amgen, Inc., Thousand Oaks, CA, ⁴Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Chronic inflammatory diseases such as rheumatoid arthritis (RA), psoriatic arthritis (PsA), and psoriasis (PsO) increase the risk of cardiovascular (CV) disease. However, it is…
Abstract Number: 1555 • 2017 ACR/ARHP Annual Meeting
Treatment Changes By Joint Activity and Skin Severity in Patients with Comorbid Psa and Pso
Philip J Mease¹, Carol J. Etzel², Jeffrey Lisse³, April W Armstrong⁴, William J Huster³, Sabrina Rebello², Rhiannon Dodge², Talia M Muram³, Sarah Al Sawah³, Mwangi J Murage³, Jeffrey D Greenberg² and William Malatestinic³, ¹Swedish Medical Center and University of Washington, Seattle, WA, ²Corrona, LLC, Southborough, MA, ³Eli Lilly and Company, Indianapolis, IN, ⁴Keck School of Medicine, University of Southern California, Los Angeles, CA
Background/Purpose: Treatment of both joint and skin symptoms is important for overall disease management of patients with psoriatic arthritis and comorbid psoriasis1,2. The objective of…
Abstract Number: 1557 • 2017 ACR/ARHP Annual Meeting
Treatment Patterns in Psoriatic Arthritis: Experience from a Real-World Setting
Martin Brom¹, Sebastian Moyano¹, Florencia Beatriz Mollerach², Luciano Fernando Lo Giudice³, Maria Laura Acosta Felquer¹, Marina Scolnik⁴, Santiago Ruta⁴ and Enrique R Soriano⁵, ¹Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Instituto Universitario Hospital Italiano de Buenos Aires, and Fundacion PM Catoggio, Buenos Aires, Argentina, ²Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ³Rheumatology section, Internal Medicine Unit, Hospital Italiano de Buenos Aires and Fundacion PM Catoggio, CABA, Argentina, ⁴Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, CABA, Argentina, ⁵Argentina, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina
Background/Purpose: Both EULAR (European League Against Rheumatism) and GRAPPA (Group for Research and Assessment of Psoriasis and Psoriatic Arthritis) recently published treatment guidelines for Psoriatic…
Abstract Number: 2309 • 2017 ACR/ARHP Annual Meeting
Risk Factors for Arthritis and the Development of Comorbid Cardiovascular and Metabolic Disease in Children with Psoriasis
Cynthia K. Manos^1,2, Rui Xiao³, Timothy G. Brandon¹, Alexis Ogdie⁴ and Pamela F. Weiss^5,6, ¹Rheumatology, Children's Hospital of Philadelphia, Philadelphia, PA, ²Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, Philadelphia, PA, ³Department of Pediatrics, Division of Biostatistics, Children's Hospital of Philadelphia, Philadelphia, PA, ⁴Rheumatology, Hospital of the University of Pennsylvania, Philadelphia, PA, ⁵Division of Rheumatology, Center for Pediatric Clincial Effectiveness, Children's Hospital of Philadelphia, Philadelphia, PA, ⁶Department of Pediatrics, Perelman School of Medicine, Philadelphia, PA
Background/Purpose: Relatively little is known about the epidemiology of juvenile psoriatic arthritis (PsA), including risk factors for development of PsA among children with psoriasis. It…
Abstract Number: 2481 • 2017 ACR/ARHP Annual Meeting
Long-Term Safety of Adalimumab (HUMIRA) in Adult Patients from Global Clinical Trials across Multiple Indications: An Updated Analysis in 29,987 Patients Representing 56,951 Patient-Years
Gerd R. Burmester¹, Remo Panaccione², Kenneth B. Gordon³, James T. Rosenbaum⁴, Dilek Arikan⁵, Winnie L. Lau⁵ and Rita Tarzynski-Potempa⁵, ¹Charité - University Medicine Berlin, Berlin, Germany, ²University of Calgary, Calgary, AB, Canada, ³Medical College of Wisconsin, Milwaukee, WI, ⁴Ophthalmology, Oregon Health & Science University and Legacy Devers Eye Institute, Portland, OR, ⁵AbbVie Inc., North Chicago, IL
Background/Purpose: Adalimumab is an anti–tumor necrosis factor-α (TNF-α) agent indicated for the treatment of immune-mediated diseases. The long-term safety of adalimumab was previously reported in…
Abstract Number: 2529 • 2017 ACR/ARHP Annual Meeting
Appraisal of the Contest Questionnaire in the Screening for Psoriatic Arthritis
Amir Haddad¹, Joy Feld^1,2, Lihi Eder³, Idit Lavi⁴, Oxana Zlazhover⁵ and Devy Zisman^1,6, ¹Rheumatology Unit Carmel Medical Center, Haifa, Israel, ²Rheumatology Unit, Carmel Medical Center, Haifa, Israel, ³Women's College Research Institute, Women's College Hospital, Toronto, ON, Canada, ⁴Epidemiology Unit Carmel Medical Center, Haifa, Israel, ⁵Bnei Zion Medical Center, Haifa, Israel, ⁶The Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel
Background/Purpose: Early diagnosis of psoriatic arthritis (PsA) is critical to prevent poor outcome. Several validated screening questionnaires have been developed to identify PsA patients in…
Abstract Number: 2531 • 2017 ACR/ARHP Annual Meeting
Utilization of the Psoriasis Epidemiology Screening Tool to Identify Signs and Symptoms of Early Psoriatic Arthritis Among Those with Psoriasis: Analysis from the Corrona Psoriasis Registry
Philip J Mease¹, Jacqueline B. Palmer², Mark Lebwohl³, Chitra Karki⁴, George W. Reed⁵, Carol J. Etzel⁶, Jeffrey D. Greenberg⁷ and Philip S. Helliwell⁸, ¹Swedish Medical Center and University of Washington, Seattle, WA, ²Novartis Pharmaceuticals Corporation, East Hanover, NJ, ³Icahn School of Medicine at Mount Sinai, New York, NY, ⁴Corrona, LLC, Southborough, MA, ⁵University of Massachusetts Medical School, Worcester, MA, ⁶The University of Texas MD Anderson Cancer Center, Houston, TX, ⁷New York University School of Medicine, New York, NY, ⁸School of Medicine, University of Leeds, Leeds, United Kingdom
Background/Purpose: The Psoriasis Epidemiology Screening Tool (PEST) is a 5-item questionnaire developed to help identify psoriatic arthritis (PsA) at an early stage, with a score…
Abstract Number: 2532 • 2017 ACR/ARHP Annual Meeting
The Relationship between the Degree of Skin Involvement and Joint Activity in Patients with Psa: Experience from the Corrona Registry
Philip J Mease¹, Carol J. Etzel², Jeffrey Lisse³, April W Armstrong⁴, William J Huster³, Sabrina Rebello², Rhiannon Dodge², Talia M Muram³, Sarah Al Sawah³, Mwangi J Murage³, Jeffrey D Greenberg² and William Malatestinic³, ¹Department of Rheumatology, Swedish Medical Center and University of Washington, Seattle, WA, ²Corrona, LLC, Southborough, MA, ³Eli Lilly and Company, Indianapolis, IN, ⁴Keck School of Medicine, University of Southern California, Los Angeles, CA
Background/Purpose: Prior studies have shown an inconsistent relationship between skin and joint symptoms in patients with comorbid PsO and PsA1-3. The objective of the…
Abstract Number: 2533 • 2017 ACR/ARHP Annual Meeting
Current Psa Therapy Impacts the Relationship between the Degree of Skin Invlovment and Joint Activity
Philip J Mease¹, Carol J. Etzel², Jeffrey Lisse³, April W Armstrong⁴, William J Huster³, Sabrina Rebello², Rhiannon Dodge², Talia M Muram³, Sarah Al Sawah³, Mwangi J Murage³, Jeffrey D Greenberg² and William Malatestinic³, ¹Swedish Medical Center and University of Washington, Seattle, WA, ²Corrona, LLC, Southborough, MA, ³Eli Lilly and Company, Indianapolis, IN, ⁴Keck School of Medicine, University of Southern California, Los Angeles, CA
Background/Purpose: Simultaneous control of joint symptoms and degree of skin involvement has been linked to improvement in health-related quality of life in patients with coexistent…
Abstract Number: 960 • 2016 ACR/ARHP Annual Meeting
Ultrasonographic Improvement of Peripheral Subclinical Enthesopathy in Therapy-Naive Patients Treated with Ustekinumab for Chronic Plaque Psoriasis: A 52-Week, Prospective, Open Label, Controlled Cohort Study
Laura Savage¹, Mark Goodfield², Elizabeth M.A. Hensor³, Paul Emery³ and Dennis McGonagle⁴, ¹NIHR Musculoskeletal Biomedical Research Unit, University of Leeds, Leeds, United Kingdom, ²Department of Dermatology, Leeds Centre for Dermatology, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ³NIHR-Leeds Musculoskeletal Biomedical Research Unit, Leeds, United Kingdom, ⁴Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom
Background/Purpose: Subclinical enthesopathy is recognised in up to 50% of psoriasis patients and is thought to precede inflammatory PsA. It is not known if effective…
Abstract Number: 2744 • 2016 ACR/ARHP Annual Meeting
Utilization of the Psoriasis Epidemiology Screening Tool (PEST) Questionnaire to Detect Psoriatic Arthritis in Clinical Practice: Data from the Validation of Psoriatic Arthritis Screening Tool for Korean Psoriasis Patients (VALOR) Study
You Jung Ha¹, Soyun Cho², Sang Heon Lee³, Yong Beom Choe⁴, Tae-Hwan Kim⁵, Joo Yeon Ko⁶, Sung Jae Choi⁷, Il-Hwan Kim⁸, Sang Woong Youn⁹ and Kichul Shin¹⁰, ¹Division of Rheumatology, Department of Internal Medicine, Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, South Korea, ²Department of Dermatology, Department of Dermatology, SMG-SNU Boramae Medical Center, Seoul, Korea, The Republic of, ³Department of Internal Medicine,Division of Rheumatology., Division of Rheumatology, Department of Internal Medicine, Konkuk University School of Medicine, Seoul, Korea, The Republic of, ⁴Department of Dermatology, Konkuk University School of Medicine, Seoul, Korea, The Republic of, ⁵Department of Rheumatology, Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ⁶Department of Dermatology, Department of Dermatology, Hanyang University College of Medicine, Seoul, Korea, The Republic of, ⁷Division of Rheumatology, Department of Internal Medicine, Korea University Ansan Hospital, Ansan, Korea, The Republic of, ⁸Department of Dermatology, Korea University Ansan Hospital, Ansan, Korea, The Republic of, ⁹Department of Dermatology, Seoul National University Bundang Hospital, Seongnam, Korea, The Republic of, ¹⁰Division of Rheumatology, Department of Internal Medicine, SMG-SNU Boramae Medical Center, Seoul, Korea, The Republic of
Background/Purpose: Several questionnaires have been developed to help identify psoriatic arthritis (PsA) among patients with psoriasis (PsO), but there is no screening tool yet tested…
Abstract Number: 1239 • 2016 ACR/ARHP Annual Meeting
Optimizing Screening for Psoriatic Arthritis through a Shortened Psoriatic Arthritis Screening and Evaluation-2 (PASE-2) Tool
Jordan Thompson¹, Marwa Darwish², So Yeon Paek³, Joseph Merola⁴, Abrar Qureshi^1,3 and M. Elaine Husni⁵, ¹Dermatology, Alpert Medical School, Brown University, Providence, RI, ²No affiliation, Boston, MA, ³Dermatology, Rhode Island Hospital, The Warren Alpert Medical School of Brown University, Providence, RI, ⁴Dermatology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, ⁵Rheumatology Dept A50, Cleveland Clinic, Cleveland, OH
Background/Purpose: The Psoriatic Arthritis Screening and Evaluation (PASE) Tool is one of the most frequently used tools to screen psoriasis patients for signs and symptoms…
Abstract Number: 2761 • 2016 ACR/ARHP Annual Meeting
Sleep Disturbance in Psoriatic Disease: Prevalence and Associated Factors
Ian Tin Yue Wong¹, Vinod Chandran², Suzanne Li³ and Dafna D Gladman⁴, ¹Faculty of Medicine, University of British Columbia, Vancouver,, BC, Canada, ²Medicine, Krembil Research Institute, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁴University of Toronto, Toronto, ON, Canada
Background/Purpose: Psoriasis is a chronic inflammatory skin disease characterized by scaling, erythematous plaques. Up to 30% of psoriasis patients develop an inflammatory arthritis termed psoriatic…
Abstract Number: 1301 • 2016 ACR/ARHP Annual Meeting
Analysis of Anatomical Sites Causing Dactylitis and Their Responsiveness to Change Under TNF-Therapy in Psoriatic Arthritis By High Resolution MRI
Dr. Philipp Sewerin, PD Dr. Stefan Vordenbäumen, Dr. Ruben Sengewein, Prof. Dr. Matthias Schneider and Prof. Dr. Benedikt Ostendorf, Department of Rheumatology & Hiller Research Unit, Heinrich-Heine University, Düsseldorf, Germany
Background/Purpose: Results: The following sites were most commonly involved in dactylitis: collateral ligament enthesitis 11/12 (92%); extensor tendons enthesitis 5/12 (42%); flexor tenosynovitis 9/12 (75%),…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].